Jim Cramer on uniQure: "This One Has Too Many Questions for Me Up Here"

uniQure N.V. (NASDAQ:QURE) is one of the stocks Jim Cramer recently talked about. A caller asked whether to buy, hold, or take profits in the stock after the release of clinical data, which indicated its gene therapy candidate significantly slowed the progression of Huntington’s disease. Cramer said:

“Yeah, I saw that news and it was really terrific. But I also saw that an insider sold about $9 million worth of stock after the run. I think that’s a, it’s a parabola, and after a parabolic move, I will not endorse it. Even if I think it’s good, I have to stay away. This one has too many questions for me up here.”

uniQure N.V. (NASDAQ:QURE) develops gene therapies for rare and severe diseases, including approved treatment HEMGENIX for hemophilia B and clinical candidates targeting Huntington’s disease, epilepsy, ALS, and Fabry disease. On September 24, the company announced positive Phase I/II results for AMT-130 in Huntington’s disease. It showed a 75% slowing of disease progression on the composite Unified Huntington’s Disease Rating Scale and 60% on Total Functional Capacity after 36 months compared to a matched control group.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.